LENZ Therapeutics (LENZ) News Today → The “Next Bitcoin”? 10 CENT Crypto Set to Explode (From True Market Insiders) (Ad) Free LENZ Stock Alerts $16.50 +0.78 (+4.96%) (As of 05:12 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineCritical Survey: LENZ Therapeutics (LENZ) and Its Competitorsamericanbankingnews.com - April 21 at 1:14 AMLENZ Therapeutics Incmorningstar.com - April 18 at 10:50 AMLENZ Therapeutics, Inc. to Post Q1 2024 Earnings of ($0.51) Per Share, Leerink Partnrs Forecasts (NASDAQ:LENZ)marketbeat.com - April 17 at 4:48 PMLENZ Therapeutics' (LENZ) "Outperform" Rating Reaffirmed at Leerink Partnrsmarketbeat.com - April 17 at 4:40 PMLENZ Therapeutics (NASDAQ:LENZ) Receives New Coverage from Analysts at SVB Leerinkmarketbeat.com - April 15 at 8:35 AMLENZ Therapeutics Inc LENZmorningstar.com - April 14 at 12:18 PMLENZ Therapeutics, Inc. Common Stock (LENZ)nasdaq.com - April 10 at 4:37 PMBlindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Saysmarkets.businessinsider.com - April 10 at 4:37 PMLENZ Therapeutics (NASDAQ:LENZ) Now Covered by Citigroupmarketbeat.com - April 10 at 9:08 AMLenz Therapeutics' eye disease drugs meet main goal of late-stage studyreuters.com - April 3 at 7:49 AMLENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trialsbusinesswire.com - April 3 at 7:00 AMLENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trialsbusinesswire.com - April 2 at 4:01 PMHuge Insider Buying From Buffett, an NFL Team Owner, a New CEO247wallst.com - March 31 at 8:55 AMLENZ Therapeutics (NASDAQ:LENZ) Research Coverage Started at Piper Sandlermarketbeat.com - March 27 at 8:18 AMInsider Buying: LENZ Therapeutics, Inc. (NASDAQ:LENZ) Director Acquires 998,009 Shares of Stockinsidertrades.com - March 26 at 4:16 AMmarketbeat.com - March 22 at 9:51 AMmarketbeat.com - March 22 at 6:11 AMmarketbeat.com - March 22 at 6:11 AM Get LENZ Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter. Email Address My top 100 stocks… (Ad)We recently ran an internal audit of every trade recommendation I’ve published across all my services… And let me tell ya, we found some incredible insights… For starters, we found about 100 stocks I trade really, really well. Get some cool freebies right here. LENZ Media Mentions By Week LENZ Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LENZ News Sentiment▼0.000.34▲Average Medical News Sentiment LENZ News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LENZ Articles This Week▼03▲LENZ Articles Average Week Get LENZ Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CDTX News Today ENTX News Today ALGS News Today AVRO News Today IKNA News Today TSBX News Today DTIL News Today ELUT News Today GNTA News Today TIL News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LENZ) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe #1 Biotech Stock to Have on Your Radar in 2024… Huge AlertsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithElon Musk Secret Crypto Plot ExposedCrypto 101 MediaGlobal crypto currency reset (41 major banks signed up)Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENZ Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
